CELL INTELLIGENCE · 肿瘤细胞治疗研究

自分泌 PD-1 阻断纳米抗体通过减轻 T 细胞耗竭增强 TCR 样 CAR-T 细胞的抗肿瘤疗效

Autocrine PD-1-blocking nanobodies enhance the antitumor efficacy of TCR-like CAR-T cells by attenuating t cell exhaustion.

局部自分泌 PD-1 检查点阻断可有效增强 TCRm CAR-T 细胞的效应功能和持久性。这种装甲 TCRm CAR-T 策略是实体瘤免疫治疗的一种有前景的治疗方法，对于靶向不同 peptide-MHC 表位的其他 TCRm CAR 系统具有广泛的转化潜力。

PARP 抑制剂联合安罗替尼作为卵巢癌装甲 CAR-T 细胞的桥接治疗可增强浸润与抗肿瘤疗效

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.

铰链区优化增强靶向 globo H 的 CAR-T 细胞在实体瘤模型中的抗肿瘤疗效

Optimization of hinge domain enhances antitumor efficacy of globo H-targeted CAR-T cells in solid tumor models.

claudin 18.2 靶向 CAR-T 细胞治疗晚期胃癌后腹膜转移的长期控制

Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer.

「CCL19 武装的溶瘤腺病毒与表达 CCR7 的 CAR-T 细胞协同抑制卵巢肿瘤生长」[Int. Immunopharmacol. 185 (2026) 116980] 的更正

Corrigendum to "CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth" [Int. Immunopharmacol.

CCL19 武装的溶瘤腺病毒与表达 CCR7 的 CAR-T 细胞协同抑制卵巢肿瘤生长

CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth.

联合靶向间皮素和腱生蛋白-C 增强卵巢癌中 CAR-T 细胞功能与肿瘤微环境调控

Combined targeting of mesothelin and tenascin-C enhances CAR-T cell function and tumor microenvironment modulation in ovarian cancer.

在卵巢癌模型中，联合靶向 MSLN 和 TNC 与 CAR-T 细胞活化改善及更广泛的微环境重塑相关。

不同的免疫细胞经嵌合抗原受体修饰后正被应用于卵巢癌：哪一种最有效？

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

卵巢癌过继细胞治疗进展

Advances in adoptive cell therapy for ovarian cancer.

红细胞膜-脂质体包被维持 CAR-T 细胞的循环稳定性与靶向肿瘤治疗

Erythrocyte membrane-liposome coating sustains circulation stability and targeted tumor therapy of CAR-T cells.

Rlip 表面工程代表了一种通用的、可在临床上转化的策略，用以克服 CAR-T 生物分布屏障。通过将红细胞模拟免疫逃逸与优化的肿瘤递送相结合，该方法改善了 CAR-T 细胞在血液系统恶性肿瘤和实体恶性肿瘤肿瘤部位的聚集。